Author: admin

The Boulder Group Arranges Sale of Net Leased Springfield Clinic

Randy Blankstein and Jimmy Goodman of The Boulder Group represented the seller in the transaction. The buyer is a commercial real estate investment firm located in Utah. The seller is a private investor located in New Jersey.

The Boulder Group, a net leased investment brokerage firm, completed the sale of a single tenant Springfield Clinic property located at 1000 W Morton Avenue in Jacksonville, IL for $1,342,588.

The 7,000-square-foot building benefits from its location along Morton Avenue, which experiences 17,200 vehicles per day. Notable retailers nearby include Walmart, Home Depot, Hy-Vee, JCPenney, Ollie’s Bargain Outlet, AT&T, Walgreens, Harbor Freight, Goodwill, McDonald’s, Subway, Taco Bell, Wendy’s, Burger King, Starbucks, and Arby’s. The property is located 1 mile from Illinois College, which has over 1,000 students.

Jacksonville is situated 35 miles west of Springfield, the Illinois state capital. The population is 22,286 within a 5-mile radius with an average household income of $82,250.

Springfield Clinic has over 10 years of lease term remaining with three 5-year renewal options. The lease features rental increases every 5 years including 4% in October 2027.

Randy Blankstein and Jimmy Goodman of The Boulder Group represented the seller in the transaction. The buyer is a commercial real estate investment firm located in Utah. The seller is a private investor located in New Jersey.

Springfield Clinic is an Illinois-based physician-owned and led healthcare provider that was founded in 1939 and is headquartered in its namesake Springfield, Illinois. Springfield Clinic has over 3,000 employees and 90 facilities throughout Illinois.

“Long-term leases to medical tenants remain attractive investments” said Randy Blankstein, President of The Boulder Group. Jimmy Goodman of The Boulder Group, added, “Investors continue to gravitate to low-rent medical assets.”

About The Boulder Group

The Boulder Group is a boutique investment real estate service firm specializing in single tenant net lease properties. The firm provides a full range of brokerage, advisory, and financing services nationwide to a substantial and diversified client base, which includes high-net-worth individuals, developers, REITs, partnerships and institutional investment funds. Founded in 1997, the firm has arranged the acquisition and disposition of over $9 billion of single tenant net lease real estate transactions. From 2014-2024, the firm was ranked in the top 10 companies in the nation for single tenant retail transactions by both Real Capital Analytics and CoStar. The Boulder Group is headquartered in suburban Chicago and has an office in Denver.

More info: www.bouldergroup.com

Media Contact
Company Name: The Boulder Group
Contact Person: Randy Blankstein
Email: Send Email
Phone: 8478816388
Address:3520 Lake Avenue Suite 203
City: Wilmette
State: Illinois
Country: United States
Website: https://www.bouldergroup.com/NNN-Properties-For-Sale.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Boulder Group Arranges Sale of Net Leased Springfield Clinic

Raymond West Intralogistics Solutions Automates Distribution Center for Leading Northwest HVAC Supplier

“Raymond West is launching a state-of-the-art automated distribution center featuring warehouse robotics and other advanced warehouse automation technologies for the Pacific Northwest’s largest HVAC supplier.”
Raymond West Intralogistics Solutions is implementing a high-tech automated distribution center for the Pacific Northwest’s largest HVAC supplier to boost efficiency and service.

Raymond West Intralogistics Solutions, a leader in material handling and logistics automation, has begun the implementation of a groundbreaking automated distribution center project for the largest HVAC supplier in the Pacific Northwest. This state-of-the-art facility integrates cutting-edge technology to enhance efficiency, reliability, and customer service in the HVAC distribution sector.

The project began in November of 2024 and is expected to be completed by November of 2025.

James Wilcox, CEO of Raymond West Intralogistics Solutions, commented on the project: “This groundbreaking automation project exemplifies our commitment to delivering optimized end-to-endless intralogistics solutions. By leveraging cutting-edge technologies like the Movu Atlas 2D pallet shuttle rack and Opex Perfect Pick systems, we’re not just improving efficiency – we’re revolutionizing how HVAC distribution centers operate in the Pacific Northwest. This project will set a new standard for the industry, showcasing how automation can address complex challenges while significantly enhancing customer service and operational performance.”

The project aims to maintain immediate and reliable customer service to building contractors throughout the Northwestern United States. By implementing fully and semi-automated storage systems for pallets, cartons, totes, and trays of HVAC components, the new distribution center addresses the challenges posed by the wide variation in product sizes and weights.

Key Features of the Automated Distribution Center

Automated Pallet Storage: The facility incorporates the Movu Atlas 2D pallet shuttle rack system, enabling fully automated high-density pallet storage. This solution optimizes warehouse space while ensuring efficient inventory management and productivity.

High-Density Storage for Medium Sized Parts: The Opex Perfect Pick system has been selected to consolidate and pick their medium sized parts, utilizing iBOT® wireless robots to deliver inventory directly to operators. This automated storage and retrieval system maintains high-density storage without compromising on efficiency.

Modular High-Density Storage for Small Parts: Small parts are stored in four Kardex Remstar Vertical Lift Modules (VLM’s). These vertical storage machines utilize large sub-divided trays with pick-to-light technology to efficiently deliver inventory to the operator and automatically store the trays with less than 1” of space between product and the storage tray above, typically saving 80% of floor space compared to shelving.

Automated Horizontal Pallet Transportation: The distribution center features autonomous mobile robots (AMRs) to safely interact with staff and other moving equipment while increasing productivity. These versatile vehicles provide horizontal transportation of order pallets from various picking areas to the shipping and production area.

Oversized Pallet Storage and Transport: Bastian CB18 automated guided forklifts (AGFs) have been deployed to efficiently move and floor stack oversized materials of various shapes and sizes across the facility. These AGFs improve product and employee safety, optimize facility space utilization, and enhance inventory tracking.

Benefits and Impact

These advanced automation solutions are expected to yield significant benefits:

  • Reduced labor requirements and increased operational efficiency
  • Improved accuracy and reliability in order fulfillment
  • Enhanced safety for employees and products
  • Optimized space utilization within the distribution center
  • Faster and more responsive customer service for building contractors

Raymond West Intralogistics Solutions’ innovative approach to this project demonstrates its commitment to providing cutting-edge automation solutions that address the unique challenges of the HVAC distribution industry. This successful implementation sets a new standard for efficiency and reliability in the sector, positioning the client at the forefront of distribution technology in the Pacific Northwest.

About Raymond West Intralogistics Solutions

At Raymond West, a Toyota Industries Company, our aim is to deliver the utmost quality and to work for continuous improvement every day, in every aspect of our business. Serving the entire West Coast, Raymond West is your trusted partner in customized intralogistics solutions and exceptional local support from 22 offices and 1,600 employees. We specialize in keeping your warehouse running efficiently, providing comprehensive services to help you Store, Move, and Optimize your operations for productivity and growth.

Media Contact
Company Name: Raymond West
Contact Person: Tracey Meyers
Email: Send Email
Phone: (800) 669-5438
Address:5560 Katella Ave
City: Cypress
State: CA
Country: United States
Website: raymondwest.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Raymond West Intralogistics Solutions Automates Distribution Center for Leading Northwest HVAC Supplier

Minh Trinh Launches Context and Scenario-Based Alerting (CSBA) to Reinvent Threat Detection for SIEM Systems

CSBA helps organizations cut costs, reduce alert fatigue, and improve cybersecurity resilience using a smarter, context-driven approach

Cybersecurity architect Minh Trinh is proud to announce the launch of the Context and Scenario-Based Alerting (CSBA) framework which is a next-generation threat detection model designed to improve the accuracy and efficiency of Security Information and Event Management (SIEM) systems.

There are several studies that highlight the need for this shift. A recent Trend Micro study found that 70% of SOC analysts believe their current SIEM tools produce too many alerts to manage. Similarly, a VikingCloud report revealed that 63% of security teams spend over four hours each week managing false positives, with 33% admitting they could not respond to cyberattacks in time due to alert overload.

CSBA was developed from the need to handle the never-ending challenges of the industry such as alert fatigue, high operational costs, and excessive false positives. The model brings a smarter, more contextualized layer to cybersecurity detection and response.

With the CSBA framework, organizations will now be able to prioritize true threats amid the noise. This is because the framework introduces a scenario-based logic system that evaluates the behavioral patterns behind security events.

Through the integration of weak signal aggregation, dynamic scoring models, and adaptive alert thresholds, CSBA is going to help streamline security operations and reduce the burden on Security Operations Center (SOC) teams.

The development of the CSBA model comes from Minh Trinh’s years of experience in SIEM architecture and security telemetry. Minh sought for a way to address the key limitations that are observed by SOCs and teams. What the CSBA model does as a way of solving this security dilemma was to note only contextually relevant data and aligning alerts to threat behaviour rather than isolated signals.

CSBA significantly reduces the amount of alerts that security systems receive and SOCs have to deal with so that there can be better decision-making at every level.

“Security teams are overwhelmed with noise, and most SIEM tools aren’t built to interpret intent or behavior,” said Minh Trinh, the creator of the CSBA model. “With CSBA, we’re not just reducing alerts—we’re helping teams understand the full story behind each event.”

CSBA uses a weighted scoring formula based on three factors: Impact, Confidence, and System Criticality. This mathematical model allows for dynamic alert prioritization, enabling teams to focus on what matters most. The framework also supports automated compliance alignment, scenario-based templates for easier configuration, and standardized data models for seamless tool integration.

About Minh Trinh

Minh Trinh is a cybersecurity architect and the developer of the Context and Scenario-Based Alerting (CSBA) framework. With deep experience in SIEM engineering, threat modeling, and security automation, Trinh focuses on building resilient, cost-effective, and intelligent detection systems that empower SOC teams to respond effectively to modern cyber threats.

Media Contact
Company Name: Minh Trinh
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.cynet.com/siem/siem-cyber-security-capabilities-4-common-challenges-solutions/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Minh Trinh Launches Context and Scenario-Based Alerting (CSBA) to Reinvent Threat Detection for SIEM Systems

Pearlem Expands Global Reach, Empowering Businesses with Comprehensive Corporate Solutions

International Corporate Service Provider Empowers Businesses Worldwide with Comprehensive Financial, Legal, and Administrative Solutions

Delaware, United States – Pearlem, a leading international corporate service provider, today announced its continued expansion and commitment to empowering businesses of all sizes with a comprehensive suite of financial, legal, and administrative solutions. With a focus on streamlining operations and facilitating growth, Pearlem offers unparalleled expertise in company incorporation, international bank account opening, and a wide array of essential corporate services across key global jurisdictions.

In an increasingly interconnected world, businesses face complex challenges when navigating international markets. Pearlem acts as a trusted partner, simplifying these complexities by providing tailored solutions designed to meet the unique needs of each client. From burgeoning startups to established small and medium-sized enterprises (SMEs) and large financial firms, Pearlem offers the guidance and support necessary to establish and thrive in today’s competitive business space.

“Our mission at Pearlem is to empower entrepreneurs and businesses by providing them with the essential tools and expertise they need to succeed on a global scale,” said a representative of Pearlem. “We understand the hurdles involved in setting up and managing a business internationally, and we are dedicated to simplifying these processes, allowing our clients to focus on their core competencies and achieve their growth objectives.”

Pearlem boasts a strong presence in several prominent international financial centers, including the United States, the United Kingdom, Singapore, and Malta. This extensive network allows the company to offer clients a diverse range of options for company incorporation, ensuring they can choose the jurisdiction that best aligns with their specific business goals and regulatory requirements.

Beyond incorporation, Pearlem helps businesses, digital nomads and financial institutions and provides invaluable assistance in opening bank accounts across the globe. Recognizing the critical role of seamless financial transactions in international business, their team of experts guides clients through the often-intricate process of establishing banking relationships in their chosen jurisdictions. This service is crucial for facilitating international trade, managing finances, and ensuring operational efficiency.

The comprehensive service portfolio of Pearlem extends beyond the initial setup phase. The company offers ongoing support in areas such as accounting and bookkeeping, ensuring clients maintain accurate financial records and comply with local regulations. Their auditing services provide an independent assessment of financial statements, fostering transparency and building trust. Pearlem also assists with tax filings, helping businesses navigate complex tax laws and optimize their tax strategies.

Furthermore, Pearlem recognizes the importance of intellectual property and offers trademark registration services to help clients protect their brand identity in their target markets. This proactive approach safeguards their valuable assets and strengthens their competitive advantage.

Pearlem leverages cutting-edge technology and cultivates long-term relationships within the industry to deliver cost-effective and efficient services. Their commitment to legal compliance is paramount, and they adhere to stringent due diligence and Know Your Client (KYC) processes to ensure the highest standards of integrity and security.

The company’s dedication to client satisfaction is reflected in the positive testimonials they have received from businesses that have benefited from their expertise. These testimonials highlight Pearlem’s efficiency, professionalism, and commitment to providing tailored solutions that meet the specific needs of each client.

With its expanded global reach and comprehensive suite of services, Pearlem Capital LLC is strategically positioned to support the growth and success of businesses navigating the complexities of the international marketplace. By simplifying corporate administration and providing expert guidance, Pearlem empowers businesses to focus on innovation, expansion, and achieving their long-term goals.

For more information visit their official website https://pearlem.com/.

About Pearlem

Pearlem is an international corporate service provider specializing in financial solutions, corporate legal structures, and bank accounts. With a presence in key global jurisdictions, Pearlem offers a comprehensive suite of services designed to empower businesses of all sizes to thrive in the international marketplace. Their commitment to efficiency, compliance, and client satisfaction makes them a trusted partner for companies seeking to expand their global footprint.

Media Contact
Company Name: Pearlem Capital LLC
Contact Person: James
Email: Send Email
Country: United States
Website: https://pearlem.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pearlem Expands Global Reach, Empowering Businesses with Comprehensive Corporate Solutions

Sjogren’s Syndrome Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Sjogren’s Syndrome Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Sjogren’s Syndrome pipeline landscape. It covers the Sjogren’s Syndrome pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Sjogren’s Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Sjogren’s Syndrome Pipeline. Dive into DelveInsight’s comprehensive report today! @ Sjogren’s Syndrome Pipeline Outlook

Key Takeaways from the Sjogren’s Syndrome Pipeline Report

  • In March 2025, Janssen Research & Development LLC announced a study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren’s syndrome (pSS) versus placebo. Sjogren’s syndrome is a chronic, progressive autoimmune disease of unclear etiology typically originating in exocrine glands and capable of affecting the function of almost any organ system in the body.
  • In March 2025, Amgen announced a study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren’s syndrome (SS). The study will enroll 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity; Population 2 will include participants with moderate to severe subjective symptoms.
  • DelveInsight’s Sjogren’s Syndrome pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Sjogren’s Syndrome treatment.
  • The leading Sjogren’s Syndrome Companies such as Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, Amgen, Rise Therapeutics and others.
  • Promising Sjogren’s Syndrome Pipeline Therapies such as Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib and others.

Stay ahead with the most recent pipeline outlook for Sjogren’s Syndrome. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Sjogren’s Syndrome Treatment Drugs

Sjogren’s Syndrome Emerging Drugs

  • VAY736: Novartis

VAY736 (ianalumab) is a novel, intravenous, defucosylated, human IgG1/κ monoclonal antibody that targets the human B cell-activating factor (BAFF) of the TNF family. The BAFF receptor is predominantly expressed on B cells and is critically involved in B cell maturation, activation, and survival. VAY736 targets the BAFF receptor and competitively inhibits BAFF binding to BAFF-R, thereby blocking BAFF-R-mediated signaling in B cells. It is also engineered to effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). The ADCC activity of ianalumab is greatly enhanced by eliminating fucose residues from the carbohydrate moiety attached to the Fc part of the antibody. The molecule is being developed by Novartis in partnership with MorphoSys as an antibody-based therapy. The drug is currently in Phase III clinical studies for the treatment of Sjögren’s Syndrome (SS).

  • AMG 329: Amgen

AMG 329 is a fully human monoclonal antibody that binds and neutralizes the function of the FLT3-ligand, thereby reducing both conventional and plasmacytoid dendritic cells. The drug is currently in Phase II clinical studies for the treatment of Sjögren’s Syndrome.

  • R-2487: Rise Therapeutics

R-2487 is a targeted oral immune therapy that has the ability to induce T regulatory cell populations. R-2487 has a unique mechanism of action by which it can engage specific immune pathways that regulate tolerance and reset T regulatory deficiencies to reduce specific inflammatory cytokines that contribute to autoimmune disease. This mechanism is particularly important in the context of treating autoimmune disease. The drug is currently in Phase I clinical studies for the treatment of Sjögren’s Syndrome.

The Sjogren’s Syndrome Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Sjogren’s Syndrome with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sjogren’s Syndrome Treatment.
  • Sjogren’s Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Sjogren’s Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sjogren’s Syndrome market

Explore groundbreaking therapies and clinical trials in the Sjogren’s Syndrome Pipeline. Access DelveInsight’s detailed report now! @ New Sjogren’s Syndrome Drugs

Sjogren’s Syndrome Companies

Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, Amgen, Rise Therapeutics and others.

Unveil the future of Sjogren’s Syndrome Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Sjogren’s Syndrome Market Drivers and Barriers

Scope of the Sjogren’s Syndrome Pipeline Report

  • Coverage- Global
  • Sjogren’s Syndrome Companies- Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, Amgen, Rise Therapeutics and others
  • Sjogren’s Syndrome Pipeline Therapies- Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib and others.
  • Sjogren’s Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Sjogren’s Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Sjogren’s Syndrome Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Sjogren’s Syndrome Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Sjogren’s syndrome: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Sjogren’s syndrome– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. VAY736: Novartis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. AMG 329: Amgen
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. R-2487: Rise Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Sjogren’s syndrome Key Companies
  21. Sjogren’s syndrome Key Products
  22. Sjogren’s syndrome- Unmet Needs
  23. Sjogren’s syndrome- Market Drivers and Barriers
  24. Sjogren’s syndrome- Future Perspectives and Conclusion
  25. Sjogren’s syndrome Analyst Views
  26. Sjogren’s syndrome Key Companies
  27. 27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sjogren’s Syndrome Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Small Fiber Neuropathy Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Small Fiber Neuropathy Pipeline Insight 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Small Fiber Neuropathy pipeline landscape. It covers the Small Fiber Neuropathy pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Small Fiber Neuropathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Small Fiber Neuropathy Pipeline. Dive into DelveInsight’s comprehensive report today! @ Small Fiber Neuropathy Pipeline Outlook

Key Takeaways from the Small Fiber Neuropathy Pipeline Report

  • DelveInsight’s Small Fiber Neuropathy pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Small Fiber Neuropathy treatment.
  • The leading Small Fiber Neuropathy Companies such as Vertex Pharmaceuticals, Biogen and others.
  • Promising Small Fiber Neuropathy Pipeline Therapies such as VX-150, Pregabalin, Ruboxistaurin, Galcanezumab and others.

Stay ahead with the most recent pipeline outlook for Small Fiber Neuropathy. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Small Fiber Neuropathy Treatment Drugs

Small Fiber Neuropathy Emerging Drugs

  • VX-150: Vertex Pharmaceuticals

Mechanism of Action: Nav1.8 voltage-gated sodium channel inhibitors. The drug is currently in phase 2 of clinical trials for the treatment of pain caused by small fiber neuropathy.

  • Vixotrigine (BIIB 074): Biogen

BIIB 074 is a voltage and use –dependent channel blocker. It is a centrally and peripherally acting small molecule. Currently, in phase 2 of clinical trials for the treatment of small fiber neuropathy.

The Small Fiber Neuropathy Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Small Fiber Neuropathy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Fiber Neuropathy Treatment.
  • Small Fiber Neuropathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Small Fiber Neuropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Fiber Neuropathy market

Explore groundbreaking therapies and clinical trials in the Small Fiber Neuropathy Pipeline. Access DelveInsight’s detailed report now! @ New Small Fiber Neuropathy Drugs

Small Fiber Neuropathy Companies

Vertex Pharmaceuticals, Biogen and others.

Small Fiber Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Parenteral
  • Molecule Type

Small Fiber Neuropathy Products have been categorized under various Molecule types such as

  • Small molecules
  • Peptide
  • Polymer
  • Monoclonal antibodies
  • Gene Therapy
  • Product Type

Unveil the future of Small Fiber Neuropathy Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Small Fiber Neuropathy Market Drivers and Barriers

Scope of the Small Fiber Neuropathy Pipeline Report

  • Coverage- Global
  • Small Fiber Neuropathy Companies- Vertex Pharmaceuticals, Biogen and others.
  • Small Fiber Neuropathy Pipeline Therapies- VX-150, Pregabalin, Ruboxistaurin, Galcanezumab and others.
  • Small Fiber Neuropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Small Fiber Neuropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Small Fiber Neuropathy Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Small Fiber Neuropathy Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Small Fiber Neuropathy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Small Fiber Neuropathy – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Small Fiber Neuropathy Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Drug name: Company name
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. BIIB 074: Biogen
  14. Drug profiles in the detailed report…..
  15. Pre-clinical and Discovery Stage Products
  16. Drug name: Company name
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Small Fiber Neuropathy Key Companies
  20. Small Fiber Neuropathy Key Products
  21. Small Fiber Neuropathy- Unmet Needs
  22. Small Fiber Neuropathy- Market Drivers and Barriers
  23. Small Fiber Neuropathy- Future Perspectives and Conclusion
  24. Small Fiber Neuropathy Analyst Views
  25. Small Fiber Neuropathy Key Companies
  26. 26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Small Fiber Neuropathy Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Metastatic Melanoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Metastatic Melanoma Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Metastatic Melanoma pipeline landscape. It covers the Metastatic Melanoma pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Metastatic Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Metastatic Melanoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Metastatic Melanoma Pipeline Outlook

Key Takeaways from the Metastatic Melanoma Pipeline Report

  • In January 2025, Melanoma Institute Australia announced a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.
  • DelveInsight’s Metastatic Melanoma pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Metastatic Melanoma treatment.
  • The leading Metastatic Melanoma Companies such as TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others.
  • Promising Metastatic Melanoma Pipeline Therapies such as TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others

Stay ahead with the most recent pipeline outlook for Metastatic Melanoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Melanoma Treatment Drugs

Metastatic Melanoma Emerging Drugs

  • EVX 01: Evaxion Biotech

EVX-01, is a novel personalized cancer immunotherapy based on Evaxion’s proprietary PIONEER™ AI technology. EVX-01 is safe and has encouraging early indications of clinically and meaningful antitumor activity. Data showed EVX-01 is capable of eliciting T-cell responses in a clinical setting where the patients received concurrent standard immune therapy, i.e. anti-PD-1 treatment. Results demonstrated an antitumor effect in combination with anti-PD-1 treatment. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.

  • IN 10018: InxMed

IN10018 is a potent and highly selective adenosine triphosphate competitive FAK inhibitor, and InxMed has its exclusive global development and commercial operation rights. Early clinical data on IN10018 showed its safety and efficacy in multiple tumor types, and the latest research results and preclinical data demonstrated that IN10018 can also be effective in combination therapies. It is expected to overcome the tumor-associated fibrosis barrier and improve local immunity, and therefore has the potential to act as an important anchor molecule in synergy with different therapeutic modalities including immunotherapy, chemotherapy, and targeted therapy. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.

  • AV MEL 1: AiVita Biomedical

AV MEL 1, is an investigational drug being developed by AiVita Biomedical. AIVITA has received IND approval to begin a Phase 1B trial investigating its cancer vaccine in patients with metastatic melanoma plus checkpoint inhibitors.

The Metastatic Melanoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.
  • Metastatic Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market

Explore groundbreaking therapies and clinical trials in the Metastatic Melanoma Pipeline. Access DelveInsight’s detailed report now! @ New Metastatic Melanoma Drugs

Metastatic Melanoma Companies

TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO Internationa LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others.

Unveil the future of Metastatic Melanoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Metastatic Melanoma Market Drivers and Barriers

Scope of the Metastatic Melanoma Pipeline Report

  • Coverage- Global

Metastatic Melanoma Companies- TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO Internationa LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others.

  • Metastatic Melanoma Pipeline Therapies- TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others
  • Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Metastatic Melanoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Metastatic Melanoma Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Melanoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Melanoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. EVX 01: Evaxion Biotech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. IN 10018: InxMed
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Melanoma Key Companies
  21. Metastatic Melanoma Key Products
  22. Metastatic Melanoma- Unmet Needs
  23. Metastatic Melanoma- Market Drivers and Barriers
  24. Metastatic Melanoma- Future Perspectives and Conclusion
  25. Metastatic Melanoma Analyst Views
  26. Metastatic Melanoma Key Companies
  27. 27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Melanoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Atopic Keratoconjunctivitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Atopic Keratoconjuctivitis Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atopic Keratoconjuctivitis pipeline landscape. It covers the Atopic Keratoconjunctivitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Keratoconjunctivitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Atopic Keratoconjunctivitis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Atopic Keratoconjunctivitis Pipeline Outlook

Key Takeaways from the Atopic Keratoconjunctivitis Pipeline Report

  • DelveInsight’s Atopic Keratoconjunctivitis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Atopic Keratoconjunctivitis treatment.
  • The leading Atopic Keratoconjunctivitis Companies such as Akari Therapeutics, Allakos, and others.
  • Promising Atopic Keratoconjunctivitis Pipeline Therapies such as Dupilumab, Cyclosporine 0.010% and others.

Stay ahead with the most recent pipeline outlook for Atopic Keratoconjunctivitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Atopic Keratoconjunctivitis Treatment Drugs

Atopic Keratoconjunctivitis Emerging Drugs Profile

  • rVA576: Akari Therapeutics

rVA576 is currently in Phase I/II of clinical trial study and is being developed by Akari Therapeutics for the treatment of Atopic Keratoconjuctivitis. Thye trial got initiated in February 2019 and is expected to get completed by February 2022.

The Atopic Keratoconjunctivitis Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Keratoconjunctivitis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Keratoconjunctivitis Treatment.
  • Atopic Keratoconjunctivitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Atopic Keratoconjunctivitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Keratoconjunctivitis market

Explore groundbreaking therapies and clinical trials in the Atopic Keratoconjunctivitis Pipeline. Access DelveInsight’s detailed report now! @ New Atopic Keratoconjunctivitis Drugs

Atopic Keratoconjunctivitis Companies

Akari Therapeutics, Allakos, and others.

Atopic Keratoconjuctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Atopic Keratoconjunctivitis Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Unveil the future of Atopic Keratoconjunctivitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Atopic Keratoconjunctivitis Market Drivers and Barriers

Scope of the Atopic Keratoconjunctivitis Pipeline Report

  • Coverage- Global
  • Atopic Keratoconjunctivitis Companies- Akari Therapeutics, Allakos, and others.
  • Atopic Keratoconjunctivitis Pipeline Therapies- Dupilumab, Cyclosporine 0.010% and others.
  • Atopic Keratoconjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Atopic Keratoconjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Atopic Keratoconjunctivitis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Atopic Keratoconjunctivitis Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Atopic Keratoconjuctivitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Atopic Keratoconjuctivitis – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Atopic Keratoconjuctivitis Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Drug Name: Company Name
  11. Mid Stage Products (Phase I/II)
  12. rVA576: Akari Therapeutics
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase I)
  15. AK002: Allakos
  16. Drug profiles in the detailed report…..
  17. Pre-clinical and Discovery Stage Products
  18. Drug Name: Company Name
  19. Drug profiles in the detailed report…..
  20. Inactive Products
  21. Atopic Keratoconjuctivitis Key Companies
  22. Atopic Keratoconjuctivitis Key Products
  23. Atopic Keratoconjuctivitis- Unmet Needs
  24. Atopic Keratoconjuctivitis- Market Drivers and Barriers
  25. Atopic Keratoconjuctivitis- Future Perspectives and Conclusion
  26. Atopic Keratoconjuctivitis Analyst Views
  27. Atopic Keratoconjuctivitis Key Companies
  28. 28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atopic Keratoconjunctivitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Alopecia Areata Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Alopecia Areata Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Alopecia Areata pipeline landscape. It covers the Alopecia Areata pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Alopecia Areata pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Alopecia Areata Pipeline. Dive into DelveInsight’s comprehensive report today! @ Alopecia Areata Pipeline Outlook

Key Takeaways from the Alopecia Areata Pipeline Report

  • In January 2025, AbbVie announced a study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA. In Study 1 and Study 2 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo.
  • DelveInsight’s Alopecia Areata pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Alopecia Areata treatment.
  • The leading Alopecia Areata Companies such as Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.
  • Promising Alopecia Areata Pipeline Therapies such as PF-06651600, STS01, Upadacitinib, ADX-914, Etrasimod, Daxdilimab, CTP-543 and others.

Stay ahead with the most recent pipeline outlook for Alopecia Areata. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Alopecia Areata Treatment Drugs

Alopecia Areata Emerging Drugs

  • Deuruxolitinib: Concert Pharmaceuticals

Concert Pharmaceuticals is developing deuruxolitinib (CTP-543), an oral inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 breakthrough therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The company is evaluating the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase III clinical program. Concert reported positive topline data from the clinical trials. Data from the clinical trials are intended to form the basis of a New Drug Application (NDA) planned to be submitted to the US Food and Drug Administration (FDA) by the first half of 2023.

  • EQ101: Equillium

EQ101 is a first-in-class, tri-specific inhibitor of IL-2, IL-9 and IL-15, three inflammatory cytokines implicated in multiple diseases. EQ101 was also shown to be well tolerated with a favorable safety profile with no drug-related SAEs and no dose-limiting toxicities. The drug is currently formulated for intravenous administration, with subcutaneous formulation development underway. It is currently in the Phase II stage of its development in alopecia areata, a dermatological autoimmune disorder.

 

  • MAX 40070: Maxinovel Pharmaceuticals

MAX-40070 is a topical JAK/Tyk2 inhibitor developed by Maxinovel. Preclinical studies have shown that topical administration of MAX-40070 could achieve an effective exposure in skin tissue while maintaining low systemic exposure. MAX-40070 has the potential to minimize the systemic side effects of oral JAK inhibitors and eventually demonstrates its high benefit/risk ratio through clinical trials, which may ultimately provide robust evidence to support its more broadly use in treating dermatological autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Alopecia Areata.

The Alopecia Areata Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Alopecia Areata with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alopecia Areata Treatment.
  • Alopecia Areata Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Alopecia Areata Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alopecia Areata market

Explore groundbreaking therapies and clinical trials in the Alopecia Areata Pipeline. Access DelveInsight’s detailed report now! @ New Alopecia Areata Drugs

Alopecia Areata Companies

Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.

Alopecia Areata pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Alopecia Areata Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Alopecia Areata Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Alopecia Areata Market Drivers and Barriers

Scope of the Alopecia Areata Pipeline Report

  • Coverage- Global
  • Alopecia Areata Companies- Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.
  • Alopecia Areata Pipeline Therapies- PF-06651600, STS01, Upadacitinib, ADX-914, Etrasimod, Daxdilimab, CTP-543 and others.
  • Alopecia Areata Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Alopecia Areata Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Alopecia Areata Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Alopecia Areata Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Alopecia Areata: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Alopecia Areata– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Deuruxolitinib: Concert Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. EQ101: Equillium
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. MAX 40070: Maxinovel Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Alopecia Areata Key Companies
  21. Alopecia Areata Key Products
  22. Alopecia Areata- Unmet Needs
  23. Alopecia Areata- Market Drivers and Barriers
  24. Alopecia Areata- Future Perspectives and Conclusion
  25. Alopecia Areata Analyst Views
  26. Alopecia Areata Key Companies
  27. 27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alopecia Areata Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Major Depressive Disorder Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Major Depressive Disorder Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Major Depressive Disorder Pipeline. Dive into DelveInsight’s comprehensive report today! @ Major Depressive Disorder Pipeline Outlook

Key Takeaways from the Major Depressive Disorder Pipeline Report

  • In April 2025, Cybin IRL Limited announced a study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
  • In April 2025, Janssen Research & Development LLC conducted a study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI]) in all participants with major depressive disorder (MDD).
  • DelveInsight’s Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment.
  • The leading Major Depressive Disorder Companies such as GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
  • Promising Major Depressive Disorder Pipeline Therapies such as NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others.

Stay ahead with the most recent pipeline outlook for Major Depressive Disorder. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Major Depressive Disorder Treatment Drugs

Major Depressive Disorder Emerging Drugs Profile

  • SAGE-217: Sage Therapeutics

SAGE-217 is an investigational, oral, novel medicine in development for depression. SAGE-217 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. Biogen and Sage Therapeutics have submitted a new drug application (NDA) to the FDA for zuranolone for the treatment of major depressive disorder (MDD).

  • REL-1017: Relmada Therapeutics Inc.

REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD.

  • Seltorexant: Minerva Sciences

Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development.

  • SP-624: Sirtsei Pharmaceuticals, Inc.

SP-624 is being studied in phase II stage of development for the treatment of major depressive disorder in comparison with placebo by Sirtsei Pharmaceuticals, Inc.

  • SPL026: Small Pharma

SPL026 (DMT), is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world’s first DMT clinical trial for depression, in collaboration with Imperial College London.

  • PDC-1421: BioLite Inc.

PDC-1421 (BLI-1005) is a Norepinephrine plasma membrane transport protein inhibitor being developed by BioLite Inc, for the treatment of major depressive disorder. The drug is currently in phase II stage of development.

The Major Depressive Disorder Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Major Depressive Disorder with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Major Depressive Disorder Treatment.
  • Major Depressive Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Major Depressive Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Major Depressive Disorder market

Explore groundbreaking therapies and clinical trials in the Major Depressive Disorder Pipeline. Access DelveInsight’s detailed report now! @ New Major Depressive Disorder Drugs

Major Depressive Disorder Companies

GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.

Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular

Major Depressive Disorder Products have been categorized under various Molecule types such as

  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy

Unveil the future of Major Depressive Disorder Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Major Depressive Disorder Market Drivers and Barriers

Scope of the Major Depressive Disorder Pipeline Report

  • Coverage- Global
  • Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
  • Major Depressive Disorder Pipeline Therapies- NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others.
  • Major Depressive Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Major Depressive Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Major Depressive Disorder Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Major Depressive Disorder Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Major Depressive Disorder: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Major Depressive Disorder – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. SAGE-217: Sage Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SP-624: Sirtsei Pharmaceuticals, Inc.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. SPL026: Small Pharma
  15. Drug profiles in the detailed report…..
  16. Preclinical Stage Products
  17. Drug Name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Major Depressive Disorder Key Companies
  21. Major Depressive Disorder Key Products
  22. Major Depressive Disorder- Unmet Needs
  23. Major Depressive Disorder- Market Drivers and Barriers
  24. Major Depressive Disorder- Future Perspectives and Conclusion
  25. Major Depressive Disorder Analyst Views
  26. Major Depressive Disorder Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Major Depressive Disorder Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies